1. Home
  2. SWIN vs CVKD Comparison

SWIN vs CVKD Comparison

Compare SWIN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWIN
  • CVKD
  • Stock Information
  • Founded
  • SWIN 2017
  • CVKD 2022
  • Country
  • SWIN Hong Kong
  • CVKD United States
  • Employees
  • SWIN N/A
  • CVKD N/A
  • Industry
  • SWIN
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • SWIN
  • CVKD Health Care
  • Exchange
  • SWIN Nasdaq
  • CVKD Nasdaq
  • Market Cap
  • SWIN 32.1M
  • CVKD 29.5M
  • IPO Year
  • SWIN 2023
  • CVKD 2023
  • Fundamental
  • Price
  • SWIN $3.75
  • CVKD $12.71
  • Analyst Decision
  • SWIN
  • CVKD Strong Buy
  • Analyst Count
  • SWIN 0
  • CVKD 1
  • Target Price
  • SWIN N/A
  • CVKD $32.00
  • AVG Volume (30 Days)
  • SWIN 284.9K
  • CVKD 36.2K
  • Earning Date
  • SWIN 08-21-2025
  • CVKD 08-06-2025
  • Dividend Yield
  • SWIN N/A
  • CVKD N/A
  • EPS Growth
  • SWIN N/A
  • CVKD N/A
  • EPS
  • SWIN N/A
  • CVKD N/A
  • Revenue
  • SWIN $3,316,000.00
  • CVKD N/A
  • Revenue This Year
  • SWIN $29.79
  • CVKD N/A
  • Revenue Next Year
  • SWIN $54.60
  • CVKD N/A
  • P/E Ratio
  • SWIN N/A
  • CVKD N/A
  • Revenue Growth
  • SWIN N/A
  • CVKD N/A
  • 52 Week Low
  • SWIN $1.16
  • CVKD $5.70
  • 52 Week High
  • SWIN $4.40
  • CVKD $22.90
  • Technical
  • Relative Strength Index (RSI)
  • SWIN 58.68
  • CVKD 49.98
  • Support Level
  • SWIN $2.93
  • CVKD $11.00
  • Resistance Level
  • SWIN $4.40
  • CVKD $13.56
  • Average True Range (ATR)
  • SWIN 0.47
  • CVKD 1.15
  • MACD
  • SWIN -0.02
  • CVKD 0.25
  • Stochastic Oscillator
  • SWIN 46.29
  • CVKD 80.97

About SWIN Solowin Holdings

Solowin Holdings Ltd is a investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secured one-stop electronic platform. It is engaged in providing securities related services, investment advisory service, and asset management service to customers. The operations were organized into four reportable segments: securities related services, investment advisory services, corporate consultancy services, and asset management services. It derives maximum revenue from investment advisory services.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: